Pillar Biosciences Inc. of Natick announced Thursday a partnership with North Carolina-based Labcorp to provide genomic testing for people with cancer.
The collaboration with Labcorp, also known as Laboratory Corp. of America Holdings, will allow for testing for DNA mutations across multiple genes using next-generation sequencing.
“This collaboration presents a broad market opportunity and bolsters our mission to make precision medicine accessible to all by providing high-quality, affordable specialty NGS testing capabilities,” said Laura Beggrow, Pillar’s chief business officer, in the press release.
Pillar specializes in oncology solutions using in-vitro diagnostics. The company announced a new CEO in September.
